|
|
||||||||
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824-1317
We have tested the hypothesis that growth factor
signaling pathways are augmented in hypertension, a disease associated
with vascular smooth muscle cell growth. Thoracic aorta was dissected from deoxycorticosterone acetate-salt (DOCA-salt) and one kidney, one
clip (1K, 1C) hypertensive rats and from sham normotensive rats for use
in isolated tissue bath experiments. Systolic blood pressure was
significantly higher in DOCA-salt and 1K, 1C than in normotensive sham
rats: 192 ± 7, 185 ± 10, and 117 ± 4 mmHg, respectively.
Although virtually no contraction to epidermal growth factor (EGF) was
observed in endothelium-denuded sham rat aorta [1 ± 1%
phenylephrine (PE) (10 µmol/l)-induced contraction], the maximal EGF-induced contraction was 45 ± 7% in endothelium-denuded aorta from DOCA-salt hypertensive rats and 39 ± 7% in aorta from 1K, 1C rats. Although slightly attenuated, a contraction to EGF was
still observed in endothelium-intact aortic strips from 28-day DOCA-salt hypertensive rats. We also conducted concentration-response curves to EGF on days 1, 3, 5, 7, 14,
and 21 of DOCA-salt therapy. A
significant contraction to EGF in aorta from DOCA-salt rats was
observed on day 14, when DOCA-salt
rats had significantly higher blood pressure than sham rats: 188 ± 6 and 122 ± 3 mmHg, respectively. Transforming growth factor-
,
an agonist of the EGF receptor, contracted DOCA-salt rat aorta (30 ± 7% PE-induced contraction) but not sham aorta (3 ± 3%). The
EGF receptor tyrosine kinase inhibitor 4,5-dianilinophthalimide (10 µmol/l), the mitogen-activated protein kinase kinase inhibitor
PD-098059 (10 µmol/l), and the L-type voltage-gated calcium channel
inhibitor diltiazem (1 mol/l), but not the cyclooxygenase inhibitor
indomethacin (10 µmol/l), virtually abolished EGF-induced contraction
(85, 98, and 99% reduction, respectively). These data support a
striking difference in EGF signaling between normotensive and
hypertensive animals. Furthermore, they provide evidence that growth
factors should be considered vasoconstrictors as well as growth
modulators in hypertension.
deoxycorticosterone acetate-salt hypertension; vascular smooth muscle; tyrosine kinases; contraction; mitogen-activated protein kinase kinase
This article has been cited by other articles:
![]() |
M. Koide, P. L. Penar, B. I. Tranmer, and G. C. Wellman Heparin-binding EGF-like growth factor mediates oxyhemoglobin-induced suppression of voltage-dependent potassium channels in rabbit cerebral artery myocytes Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1750 - H1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ogden, J. M. Thompson, Z. Hickner, T. Huang, D. D. Tang, and S. W. Watts A new signaling paradigm for serotonin: use of Crk-associated substrate in arterial contraction Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2857 - H2863. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Spurrell, T. V. Murphy, and M. A. Hill Intraluminal pressure stimulates MAPK phosphorylation in arterioles: temporal dissociation from myogenic contractile response Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1764 - H1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lorita, N. Escalona, S. Faraudo, M. Soley, and I. Ramirez Effects of epidermal growth factor on epinephrine-stimulated heart function in rodents Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1887 - H1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Che and P. K. Carmines Angiotensin II Triggers EGFR Tyrosine Kinase-Dependent Ca2+ Influx in Afferent Arterioles Hypertension, November 1, 2002; 40(5): 700 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Watts Serotonin-Induced Contraction in Mesenteric Resistance Arteries: Signaling and Changes in Deoxycorticosterone Acetate-Salt Hypertension Hypertension, March 1, 2002; 39(3): 825 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Florian, A. Dorrance, R. C. Webb, and S. W. Watts Mineralocorticoids upregulate arterial contraction to epidermal growth factor Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R878 - R886. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Dorrance, H. L. Osborn, R. Grekin, and R. C. Webb Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R944 - R950. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. MA and S. C. SANSOM Epidermal Growth Factor Activates Store-Operated Calcium Channels in Human Glomerular Mesangial Cells J. Am. Soc. Nephrol., January 1, 2001; 12(1): 47 - 53. [Abstract] [Full Text] |
||||
![]() |
E. N. T. P. Bakker, E. T. van der Meulen, J. A. E. Spaan, and E. VanBavel Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1233 - H1240. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |